Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099986 | 0.92 | HPGD (0.38) | IDH2MAPTPTGS2 | |
| SCHEMBL5099439 | 0.91 | CHRM3 (0.45) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5103918 | 0.90 | FABP4 (0.39) | CHRM3IDH2HTT | |
| SCHEMBL5103759 | 0.87 | CHRM3 (0.41) | CHRM3IDH2CHRM2CHRM1MEN1 | |
| SCHEMBL5112458 | 0.86 | CHRM3 (0.41) | CHRM3IDH2CHRM2CHRM1 | |
| SCHEMBL3912448 | 0.86 | CHRM3 (0.50) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5103241 | 0.85 | CHRM3 (0.38) | CHRM3CHRM2CHRM1GRIN2B | |
| SCHEMBL5107027 | 0.85 | CHRM3 (0.45) | CHRM3IDH2CHRM2CHRM1 | |
| SCHEMBL5099516 | 0.83 | CHRM3 (0.50) | CHRM3IDH2CHRM2CHRM1 | |
| SCHEMBL5113768 | 0.83 | KMT2A (0.42) | CHRM3MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885ABL1 4582/4885IDH2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.